Read by QxMD icon Read

progression after second line chemotherapy prostate cancer

Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC). METHODS: Thirty-one mCRPC patients with progressive disease despite second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic(68)Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Included patients then underwent quarterly (177)Lu-DKFZ-PSMA-617 therapy...
August 10, 2016: European Journal of Nuclear Medicine and Molecular Imaging
Dimitrios Papazoglou, Luciano Wannesson, Dominik Berthold, Richard Cathomas, Silke Gillessen, Christian Rothermundt, Loretta Hasler, Ralph Winterhalder, Andreas Barth, Walter Mingrone, Catrina Uhlmann Nussbaum, Lukas von Rohr, Philippe von Burg, Mathias Schmid, Jürg Richner, Sylvia Baumann, Reto Kühne, Frank Stenner, Sacha I Rothschild
BACKGROUND: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that binds to and blocks the AR with higher affinity than previously available AR inhibitors. High activity has been proven in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and in chemotherapy-naive patients with mCRPC. However, its activity in patients previously treated with other novel agents (for example, abiraterone and/or cabazitaxel), remains controversial...
June 23, 2016: Clinical Genitourinary Cancer
Ankit Madan, Benjamin S Jones, Rodolfo Bordoni, Mansoor N Saleh, Mary S Jerome, Deborah K Miley, Bradford E Jackson, Francisco Robert
PURPOSE: Given the success of cabazitaxel in patients with prostate cancer who progressed after receiving prior chemotherapy, its preclinical efficacy in various cell lines and possible ability to cross blood-brain barrier, cabazitaxel was hypothesized to increase objective response rate (ORR) in second-line setting in non-small cell lung cancer (NSCLC). METHODS: This was a phase II 2-stage trial in 28 patients using two different treatment schedules (A: 20 mg/m(2) every 3 weeks intravenously and B: 8...
September 2016: Cancer Chemotherapy and Pharmacology
Arndt Katzenwadel, Philipp Wolf
Androgen deprivation therapy (ADT) is considered as the standard therapy for men with de novo or recurrent metastatic prostate cancer. ADT commonly leads to initial biochemical and clinical responses. However, several months after the beginning of treatment, tumors become castration-resistant and virtually all patients show disease progression. At this stage, tumors are no longer curable and cancer treatment options are only palliative. In this review, we describe molecular alterations in tumor cells during ADT, which lead to deregulation of different signaling pathways and castration-resistance, and how they might interfere with the clinical outcome of different second-line therapeutics...
October 10, 2015: Cancer Letters
Hannelore V Heemers, James L Mohler
Ever since the Noble prize-winning findings of Huggins and Hodges, the androgen receptor (AR) has been the main target for treatment of advanced prostate cancer (CaP). Today, second- and even third-line androgen deprivation strategies, which have been designed rationally to interfere with the AR signaling that re-emerges under conditions of androgen deprivation and is at least in part responsible for disease recurrence, are effective in impeding progression of advanced CaP. The therapeutic success of these novel agents in CaP that has failed initial androgen deprivation therapy (ADT) and subsequent chemotherapy is prompting studies to explore their use earlier in the course of CaP progression...
2014: American Journal of Clinical and Experimental Urology
Andressa Ardiani, Sofia R Gameiro, Anna R Kwilas, Renee N Donahue, James W Hodge
Despite recent advances in diagnosis and management, prostrate cancer remains the second most common cause of death from cancer in American men, after lung cancer. Failure of chemotherapies and hormone-deprivation therapies is the major cause of death in patients with castration-resistant prostate cancer (CRPC). Currently, the androgen inhibitors enzalutamide and abiraterone are approved for treatment of metastatic CRPC. Here we show for the first time that both enzalutamide and abiraterone render prostate tumor cells more sensitive to T cell-mediated lysis through immunogenic modulation, and that these immunomodulatory activities are androgen receptor (AR)-dependent...
October 15, 2014: Oncotarget
Cheol Kwak, Tony Tong Lin Wu, Hyun Moo Lee, Hsi Chin Wu, Sung Joon Hong, Yen Chuan Ou, Seok Soo Byun, Hyou Young Rhim, Thian Kheoh, Ying Wan, Howard Yeh, Margaret K Yu, Choung Soo Kim
OBJECTIVES: To evaluate the safety and efficacy of abiraterone acetate and prednisolone in Korean and Taiwanese patients with metastatic castration-resistant prostate cancer not responding to docetaxel-based chemotherapy. METHODS: In this single-arm study, 82 metastatic castration-resistant prostate cancer patients who failed docetaxel-based chemotherapy were treated with abiraterone (1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients achieving a prostate-specific antigen decline ≥ 50% were considered as responding...
December 2014: International Journal of Urology: Official Journal of the Japanese Urological Association
A Irelli, G Bruera, K Cannita, E Palluzzi, G L Gravina, C Festuccia, C Ficorella, E Ricevuto
Different options are available as second-line treatment of metastatic castrate-resistant prostate cancer: cabazitaxel, abiraterone, and enzalutamide. Phase III studies evaluating cabazitaxel and the two hormonal agents have been shown to significantly prolong overall survival compared to mitoxantrone and placebo, respectively. Several studies have also demonstrated feasibility and activity of docetaxel rechallenge in case of a sufficient progression-free interval (3-6 months), good performance status, and previous acceptable safety profile, thus providing an additional treatment option in clinical practice...
2014: BioMed Research International
Kazuhiro Matsumoto, Masayuki Hagiwara, Nozomi Hayakawa, Nobuyuki Tanaka, Yujiro Ito, Takahiro Maeda, Akiharu Ninomiya, Hirohiko Nagata, So Nakamura
The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English...
2014: Asian Pacific Journal of Cancer Prevention: APJCP
Naoto Kamiya, Hiroyoshi Suzuki, Kensaku Nishimura, Motohiro Fujii, Takatsugu Okegawa, Tadashi Matsuda, Tatsuo Morita, Yoshio Takihana, Seiichiro Ozono, Mikio Namiki, Akio Matsubara, Tomohiko Ichikawa, Tsuneharu Miki
OBJECTIVES: To clarify clinical predictors for a prostate-specific antigen decrease ≥50% in response to alternative non-steroidal antiandrogen therapy and to develop a nomogram to predict the prostate-specific antigen decrease ≥50% in response to alternative non-steroidal antiandrogen therapy in patients with advanced prostate cancer that relapsed after initial combined androgen blockade. We previously reported that combined androgen blockade with an alternative non-steroidal antiandrogen is effective for advanced prostate cancer that has relapsed after initial combined androgen blockade...
March 2014: Japanese Journal of Clinical Oncology
Axel Heidenreich, Patrick J Bastian, Joaquim Bellmunt, Michel Bolla, Steven Joniau, Theodor van der Kwast, Malcolm Mason, Vsevolod Matveev, Thomas Wiegel, Filiberto Zattoni, Nicolas Mottet
OBJECTIVE: To present a summary of the 2013 version of the European Association of Urology (EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostate cancer (CRPC). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2011-2013). The guidelines were updated, and levels of evidence and/or grades of recommendation were added to the text based on a systematic review of the literature that included a search of online databases and bibliographic reviews...
February 2014: European Urology
Frederik Birkebaek Thomsen, Martin Andreas Røder, Per Rathenborg, Klaus Brasso, Michael Borre, Peter Iversen
OBJECTIVE: The aim of this study was to record prostate-specific antigen (PSA) response and overall survival (OS) for a group of metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide following progression after abiraterone treatment in the post-chemotherapy setting. MATERIAL AND METHODS: Twenty-four mCRPC patients with progression after abiraterone treatment following primary docetaxel therapy received enzalutamide 160 mg/day...
June 2014: Scandinavian Journal of Urology
Susan Halabi, Chen-Yen Lin, Eric J Small, Andrew J Armstrong, Ellen B Kaplan, Daniel Petrylak, Cora N Sternberg, Liji Shen, Stephane Oudard, Johann de Bono, Oliver Sartor
BACKGROUND: Several prognostic models for overall survival (OS) have been developed and validated in men with metastatic castration-resistant prostate cancer (mCRPC) who receive first-line chemotherapy. We sought to develop and validate a prognostic model to predict OS in men who had progressed after first-line chemotherapy and were selected to receive second-line chemotherapy. METHODS: Data from a phase III trial in men with mCRPC who had developed progressive disease after first-line chemotherapy (TROPIC trial) were used...
November 20, 2013: Journal of the National Cancer Institute
Andrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, Jeremy Sharib, Charles J Ryan, David C Smith, Lance C Pagliaro, Tomasz M Beer, Glenn Liu, Eric J Small
BACKGROUND: Mitoxantrone plus prednisone and ixabepilone each have modest activity as monotherapy for second-line chemotherapy in patients with docetaxel-refractory castration-resistant prostate cancer. Clinical noncross- resistance was previously observed. Phase 1 testing determined the maximum tolerated dose and dose-limiting toxicities with the combination regimen; a phase 2 study was conducted to evaluate the activity of the combination. METHODS: Patients with metastatic progressive castration-resistant prostate cancer during or after 3 or more cycles of taxane-based chemotherapy enrolled in a phase 2 multicenter study of ixabepilone 35 mg/m(2) and mitoxantrone 12 mg/m(2) administered on Day 1 every 21 days with pegfilgrastim support, along with prednisone 5 mg twice daily...
June 1, 2011: Cancer
Lauren C Harshman, Mary-Ellen Taplin
Abiraterone acetate is the first second-line hormonal agent proven to improve survival in metastatic castration-resistant prostate cancer. It selectively inhibits cytochrome P450 17 (CYP17) α-hydroxylase and cytochrome17,20 (C17,20)-lyase, which are enzymes critical for androgen synthesis. Abiraterone acetate was initially approved in the United States in 2011 after demonstrating a 4-month survival benefit in docetaxel-refractory metastatic prostate cancer. The FDA recently expanded its indication for use in the pre-chemotherapy setting after it elicited significant delays in disease progression and a strong trend for increased overall survival in phase III studies...
August 2013: Advances in Therapy
Angel Segura Huerta, Encarnación Reche Santos, Gema Bruixola Campos, Carmen Salvador Coloma, Oscar Niño Gómez
INTRODUCTION: To date, there are no guidelines for a rational and more favourable sequence of treatment after docetaxel. Two drugs (cabazitaxel and abiraterone) have recently been approved as second-line treatment after docetaxel failure in metastatic castration-resistant prostate cancer (mCRPC), but there are no studies comparing abiraterone versus cabazitaxel. The most suitable drug is chosen based on the physician's opinion and the patient's characteristics. In patients with a good performance status who are able to receive either treatment, it would be convenient to begin with cabazitaxel and to reserve abiraterone in case there is a worsening of the general status, in consideration of abiraterone's more favourable toxicity profile...
May 2013: Case Reports in Oncology
R Iacovelli, A Altavilla, G Procopio, S Bracarda, M Santoni, S Cascinu, E Cortesi
BACKGROUND: About 20% of patients with prostate cancer have an ECOG performance status (PS) 2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2. METHODS: PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected...
December 2013: Prostate Cancer and Prostatic Diseases
Enrique Gallardo, José Ángel Arranz, José Pablo Maroto, Luis Ángel León, Joaquim Bellmunt
The term castration-resistant prostate cancer (CRPC) encompasses a wide variety of patients with different prognoses. The combination of docetaxel and prednisone is considered as the standard first-line chemotherapy. For years, patients progressing on docetaxel have been managed with second- and third-line hormone therapies, re-treatment with docetaxel, or combined mitoxantrone and prednisone. Recently published results of four studies using different drugs: cabazitaxel (CBZ), abiraterone (AA), enzalutamide (ENZ), and radium 223, showed an increased survival in such patients...
November 2013: Critical Reviews in Oncology/hematology
Ana M Aparicio, Andrea L Harzstark, Paul G Corn, Sijin Wen, John C Araujo, Shi-Ming Tu, Lance C Pagliaro, Jeri Kim, Randall E Millikan, Charles Ryan, Nizar M Tannir, Amado J Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F Thall, Christopher J Logothetis
PURPOSE: Clinical features characteristic of small-cell prostate carcinoma (SCPC), "anaplastic," often emerge during the progression of prostate cancer. We sought to determine the efficacy of platinum-based chemotherapy in patients meeting at least one of seven prospectively defined "anaplastic" clinical criteria, including exclusive visceral or predominantly lytic bone metastases, bulky tumor masses, low prostate-specific antigen levels relative to tumor burden, or short response to androgen deprivation therapy...
July 1, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
(no author information available yet)
First-line treatment based on androgen suppression is initially very effective in relieving the symptoms of metastatic prostate cancer. When androgen suppression no longer controls disease progression and symptoms, which treatments are known to improve duration or quality of survival? To answer this question, we reviewed the evidence using the standard Prescrire methodology. Low doses of corticosteroids, such as prednisone 5 to 10 mg per day, appear to improve quality of life for a few months by relieving symptoms in 20% to 40% of patients...
March 2013: Prescrire International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"